PGLS (6-phosphogluconolactonase) is a cytoplasmic enzyme that catalyzes the hydrolysis of 6-phosphogluconolactone to 6-phosphogluconate, a critical step in the oxidative branch of the pentose-phosphate pathway. This metabolic function supports cellular NADPH production and biosynthetic processes essential for normal cell function. However, the provided PubMed abstracts focus exclusively on paragangliomas (PGLs)—neuroendocrine tumors arising from sympathetic or parasympathetic ganglia—and do not contain information regarding PGLS gene function, mechanism, or disease relevance. The abstracts discuss paraganglioma genetics (including mutations in SDHx, VHL, EPAS1, and other susceptibility genes), pathophysiology driven by hypoxia signaling and catecholamine production, and clinical management strategies, but they do not mention PGLS or 6-phosphogluconolactonase. Therefore, specific information about PGLS involvement in paraganglioma pathogenesis or other disease states cannot be substantiated from the provided literature. Further investigation into PGLS-specific research would be required to establish clinical significance beyond its established metabolic role in pentose-phosphate metabolism.